stockrow
Monday 9 November 2026
Export NGEN’s income statement to Excel — free account
NervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
1.33
0.01
+0.76%
Follow NGEN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (18) | (32) | (16) | +80.6% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (18) | (32) | (16) | +80.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (0.26) | (0.40) | (0.24) | +52.3% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.18) | (0.19) | (0.20) | +5.6% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.18) | (0.19) | (0.20) | +5.6% | ||||||
| Book value | — | — | — | — | — | — | — | — | 0.03 | 0.06 | 0.37 | +109.0% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 67 | 72 | 79 | +7.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (12) | (14) | (18) | +13.5% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (12) | (14) | (18) | +13.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 2 | 4 | 34 | +154.8% | |||||
| Net debt | — | — | — | — | — | — | — | — | (13) | (16) | (63) | +24.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 2 | 4 | 34 | +124.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (205.27) | (40.66) | (205.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (1,037.45) | (94.85) | (1,037.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 9 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
NervGen Pharma Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| MSLE Satellos Bioscience Inc. | $152.6M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $148.4M | — (loss-making) | — (loss-making) | +47.62% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| SION Sionna Therapeutics, Inc. | $148.3M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| NGEN NervGen Pharma Corp. | $143.1M | — (loss-making) | — | — | n/m | −48.10% (below 0%: shrinking) | — | 0.00% | |
| VRXA Veraxa Biotech AG | $140.4M | — | — | — | — | — | — | — | Compare |
| ADAG Adagene Inc. Sponsored ADR | $134.3M | — | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $148.4M | — | — | −83.19% | — | +7.91% | 100.00% | 0.00% |